liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy
Linköpings universitet, Institutionen för medicin och hälsa, Lungmedicin. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Centrum för kirurgi, ortopedi och cancervård, Lungmedicinska kliniken US. Östergötlands Läns Landsting, Hjärt- och Medicincentrum, Allergicentrum US.
Linköpings universitet, Institutionen för klinisk och experimentell medicin. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Centrum för hälso- och vårdutveckling, Regionalt cancercentrum.
Linköpings universitet, Institutionen för medicin och hälsa, Internmedicin. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Hjärt- och Medicincentrum, Allergicentrum US.ORCID-id: 0000-0002-8365-3132
Uppsala University, Sweden .
Vise andre og tillknytning
2013 (engelsk)Inngår i: European Journal of Cancer, ISSN 0959-8049, E-ISSN 1879-0852, Vol. 49, nr 1, s. 115-120Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Aim of the study: The primary purpose of this study is to investigate if pretreatment plasma levels of vascular endothelial growth factor (VEGF) are predictive of the effect of celecoxib on survival in advanced non-small cell lung cancer (NSCLC) treated with palliative chemotherapy. A secondary objective is to describe the course of plasma VEGF levels during and after treatment with cytotoxic chemotherapy combined with celecoxib or placebo. less thanbrgreater than less thanbrgreater thanMethods: In a previously published double-blind multicenter phase III trial, 316 patients with NSCLC stage IIIB or IV and World Health Organisation (WHO) performance status 0-2 were randomised to receive celecoxib 400 mg b.i.d. or placebo in combination with two-drug platinum-based chemotherapy. Chemotherapy cycle length was three weeks and planned duration of chemotherapy was four cycles. Celecoxib was given for a maximum of one year but was stopped earlier in case of disease progression or prohibitive toxicity. In a subset of patients, plasma VEGF levels were examined at onset of treatment and at 6, 12 and 20 weeks. less thanbrgreater than less thanbrgreater thanResults: VEGF levels at start of treatment were obtained in 107 patients at four study sites. The median value was 70 pg/ml. Mean values declined during the first 12 weeks and then increased at 20 weeks. A subpopulation treatment effect pattern plot (STEPP) analysis showed an inverse relationship between initial plasma VEGF and the impact of celecoxib on survival with zero effect at 200 pg/ml. The effect on survival by celecoxib in the whole subset of patients was positive (hazard ratio (HR)=0.64 [confidence interval (CI) 0.43-0.95], p=0.028). less thanbrgreater than less thanbrgreater thanConclusion: Low pretreatment plasma levels of VEGF appear to be predictive of a positive effect of celecoxib on survival.

sted, utgiver, år, opplag, sider
Elsevier , 2013. Vol. 49, nr 1, s. 115-120
Emneord [en]
Non-small cell lung cancer, Celecoxib, Chemotherapy, Survival, Plasma VEGF
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-88362DOI: 10.1016/j.ejca.2012.07.032ISI: 000312896700015OAI: oai:DiVA.org:liu-88362DiVA, id: diva2:602881
Merknad

Funding Agencies|Ostergotland County Council, Medical Research Council of South-East Sweden (FORSS)||

Tilgjengelig fra: 2013-02-04 Laget: 2013-02-04 Sist oppdatert: 2017-12-06

Open Access i DiVA

fulltext(445 kB)608 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 445 kBChecksum SHA-512
b53dc4663d954c5f94217dccae813337bcf8efbaebda2ad11a3e421178ac60697f3ad166259323f91c9a7a1bf00a9c51f0f5d2e7d74676bb4148eb9d0f10f5bc
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekst

Personposter BETA

Sörenson, SverreFohlin, HelenaLindgren, AndreaSederholm, ChristerClinchy, Birgitta

Søk i DiVA

Av forfatter/redaktør
Sörenson, SverreFohlin, HelenaLindgren, AndreaSederholm, ChristerClinchy, Birgitta
Av organisasjonen
I samme tidsskrift
European Journal of Cancer

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 608 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 460 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf